Capital raised by NurExone Biologic
3 Form D filings · first filed Apr 2025
Chief Financial Officer
Signatory on NurExone Biologic's Form D filings · $2.2M raised across 3
Eran Ovadya is on file as Chief Financial Officer at NurExone Biologic. NurExone Biologic has 3 Form D filings on record, $2.2M raised in total. Eran Ovadya appears as a signatory on the company's filings.
ExoPTEN is an exosome-loaded nanodrug designed to facilitate neuron regeneration and restore motor, sensory, and functional abilities in patients who have recently experienced acute spinal cord injuries.
